About My Health Careers Internship MedBlogs Contact us
Medindia LOGIN REGISTER
Advertisement

COPD may Be Helped by Drug Combination

by Rajashri on August 17, 2008 at 12:14 PM
Font : A-A+

 COPD may Be Helped by Drug Combination

Drug therapy appears to reduce lung function loss in patients with moderate to severe chronic obstructive pulmonary disease (COPD), a trial in 42 countries indicates.

The Toward a Revolution in COPD Health (TORCH) study investigated the effects of combined salmeterol, a B-agonist, and fluticasone propiniate, an inhaled cortical steroid, either alone or in combination, on mortality, exacerbations, health-related quality of life and rate of decline in lung function as measure by forced expiratory volume in one second (FEV1) in patients with COPD.

Advertisement

The study has been published in the second issue for August of the American Journal of Respiratory and Critical Care Medicine, published by the American Thoracic Society.

"Pharmacotherapy with salmeterol plus fluticasone propionate, or the components, reduces the rate of decline on FEV1 in patients with moderate to severe COPD, thus slowing disease progression," said Bartolome R. Celli, M.D., lead author of the study and professor at Tufts University School of Medicine.
Advertisement

"To date, smoking cessation is the only intervention that has conclusively been shown to alter the rate of decline in FEV1," said Dr. Celli.

This is the first demonstration of an effective pharmacothrerapy in COPD.

The TORCH study randomized more than 6,000 patients with moderate to severe COPD from 42 countries to receive either salmeterol, fluticasone propionate, the two in combination, or placebo.

After baseline FEV1 was recorded, patients were re-evaluated every 24 weeks to determine the rate of decline in FEV1.

"The rate of decline in FEV1 was slowest in patients on SFC and fastest in those randomized to the placebo arm," said Dr. Celli.

"From week 24 onward, the adjusted rate of decline in FEV1 was 39ml/year for SFC, 42 ml/year for both SAL and FP and 55 ml/year for placebo," the researcher added.

Although the study was not formally powered to detect differences in rate of decline of FEV1, the results were highly significant. The rate of decline in treatment groups was similar across a number of variables, including sex, age, ethnicity and body mass index. Furthermore, the slower rate of decline in FEV1 appeared to be associated with a lower risk of exacerbation.

Source: ANI
RAS/N
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Advertisement
News Category
What's New on Medindia
January is the Thyroid Awareness Month in 2022
Menstrual Disorders
Coffee May Help You Fight Endometrial Cancer
View all

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Drug Toxicity Signature Drug Toxicity Pneumoconiosis Pulmonary Arterial Hypertension Chronic Obstructive Pulmonary Disease Emphysema Pneumonectomy Chronic Bronchitis 

Recommended Reading
Respiratory Diseases
Respiratory diseases affect any part of the respiratory system. Some of the lung diseases like ......
Health Loss Due to Type 2 Diabetes Expected to Double in Australia by 2023
Researchers have predicted that health loss by type 2 diabetes will be more than double in ......
Health Fears Over Exploration Oil Deal Raised in Kenya
Kenyan activists on Monday called for a Swedish firm's plans to search for oil and natural gas in .....
Chronic Bronchitis
Chronic bronchitis is a type of chronic obstructive pulmonary disorder that causes obstruction to ai...
Chronic Obstructive Pulmonary Disease
COPD includes respiratory tract disorders that cause obstruction to airflow. These are chronic br...
Drug Toxicity
Drug toxicity is an adverse reaction of the body towards a drug that results as a side effect of a d...
Emphysema
Emphysema is a chronic obstructive pulmonary disease, marked by alveolar damage, and reduced air flo...
Pneumoconiosis
Pneumoconiosis is a group of lung diseases caused by inhaled dust particles. It causes inflammation ...
Pulmonary Arterial Hypertension
It can be a serious condition affecting the heart. It is defined as mean pulmonary arterial pressure...

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2022

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use
open close
CONSULT A DOCTOR
I have read and I do accept terms of use - Telemedicine

Advantage Medindia: FREE subscription for 'Personalised Health & Wellness website with consultation' (Value Rs.300/-)